Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$25.01M-17.6%-$23.52M-15.8%-$20.77M-29.1%-$21.53M-23.2%-$21.25M-19.1%
$692K+8.0%$666K+6.1%$666K+8.5%$662K+5.6%$641K+6.3%
$1.87M+20.4%$1.59M-22.4%$1.59M-27.2%$1.63M-14.5%$1.55M+4.5%
-$20.36M+11.4%-$20.95M-5.6%-$14.73M-0.5%-$19.2M-65.4%-$22.98M-67.9%
$415K-60.7%$242K-52.6%$421K+558%$600K+525%$1.06M+127%
$17.59M-16.7%$15.32M+53.6%$16.04M+1,760%$16.28M+112%$21.12M+1,466%
$283.27M-$112K-147%
$280.5M+14,611%-$5.75M+40.3%$0+100%-$2.96M-114%-$1.93M+86.1%
-$20.77M+13.6%-$21.19M-4.1%-$15.15M-2.9%-$19.8M-69.1%-$24.04M-69.9%

FAQ

How much cash does Artiva Biotherapeutics, Inc. generate?
Artiva Biotherapeutics, Inc. (ARTV) generated -$75.2M in operating cash flow over the trailing twelve months.
What is Artiva Biotherapeutics, Inc.'s free cash flow?
After $1.7M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$76.9M over the trailing twelve months, down 8.6% year over year.
Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.